Dianthus Therapeutics, Inc.
DNTH
$78.86
-$0.04-0.05%
NASDAQ
Corporate Info
Website
Phone Number
929 999 4055
Address
7 Times Square
43rd Floor
New York, NY 10036
43rd Floor
New York, NY 10036
Country
United States
Year Founded
2019
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
92
Business Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.